Globally, the health care sector is in a period of intense fluctuation that has opened unique opportunities for development and optimization within the industry. In this rapidly changing landscape, technological advances have made many new procedures and methods of diagnosis and treatment possible. Less invasive surgical techniques continue to be at the forefront of development to improve the quality of life for people and greatly improve the survival rates of all patients.
SANUWAVE Health, Inc. is an emerging leader in the regenerative medicine category focused in four specialized areas: wound, orthopedic/spine, plastic/cosmetic and cardiac. Our goal is to provide cost competitive solutions for unmet medical needs.
Pulsed Acoustic Cellular Expression (PACE) technology delivers high energy, acoustic pressure waves, delivered in the shock wave spectrum, to activate biologic signaling and angiogenic responses, including revascularization and microcirculation, helping to restore normal healing processes and regeneration. The PACE technology mechanisms are applicable to multiple indications and markets.
The product development pipeline and preclinical and pilot clinical research is targeting degenerative disease and non-healing injuries in orthopedics, plastic and cosmetic regenerative medicine in conditions like cellulite and ultimate product candidates for the break up of plaque in arteries and regenerative capabilities in the heart. SANUWAVE’s lead product dermaPACE alone addresses a $10 billion global advanced wound care market opportunity.
dermaPACE is currently under review by the U.S. Food and Drug Administration (FDA) for Premarket Approval and is not available for sale or distribution in the U.S.